IPSCO Tubulars IPSC 深 滬
已收盤 12-24 16:00:00 美东时间
1.04
+0.061
+6.19%
華盛通- 最 高1.09
- 今 開0.952
- 成交量 186.26万股
- 最 低 0.9515
- 昨 收 0.9794
- 總市值 9079.94万
- 52周最高 1.185
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.3418
- 委 比 -83.39%
- 總股本 8730.71万
- 歷史最高 32.899
- 量 比 0.64
- 振 幅 14.14%
- 歷史最低 0.3418
- 每 手 1
- 風險率 0.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
11-18 15:28
Leerink Partners Downgrades Century Therapeutics to Market Perform, Lowers Price Target to $2
Leerink Partners analyst Daina Graybosch downgrades Century Therapeutics (NASDAQ:IPSC) from Outperform to Market Perform and lowers the price target from $7 to $2.
11-17 20:29
Century Therapeutics Q3 EPS $(0.40) Misses $(0.34) Estimate
Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.34) by 18.34 percent. This is a 8.11 percent decrease over losses of $(0.37) per share
11-13 20:34
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
Century Therapeutics announced that its Chief Scientific Officer, Chad Cowan, Ph.D., will present at Chardan’s 9th Annual Genetic Medicines Conference on October 21, 2025, in New York. The presentation will be live-streamed on Century’s website and available for replay for 30 days. Century Therapeutics is a biotech company developing iPSC-derived cell therapies for autoimmune diseases and cancer using its Allo-Evasion™ technology. For more inform...
10-14 20:01
Analysts Offer Insights on Healthcare Companies: HCW Biologics (HCWB) and Century Therapeutics (IPSC)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
09-08 16:20
CytoMed Expands Clinical-Scale NK Cells From Decade-Old Cord Blood; Forms New Cord Blood-Derived Biotech Under LongevityBank To Drive Growth And Revenue
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived
08-28 21:07
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Century Therapeutics' CEO Brent Pfeiffenberger will present at the H.C. Wainwright Global Investment Conference on September 9-10, 2025, in New York. An on-demand webcast of the presentation will be available on September 5, 2025, on the company’s website. Century Therapeutics is a biotech company developing iPSC-derived cell therapies for autoimmune diseases and cancers, focusing on off-the-shelf therapies to expand patient access.
08-22 12:00
Shineco Launches Blockchain-Driven Cell Technology Division to Speed Global Stem Cell Product Distribution
Shineco Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, today announced the establishment of a Biological Cell Digital Business
08-13 18:33
Century Therapeutics Announces Major Workforce Reduction
An announcement from Century Therapeutics ( ($IPSC) ) is now available. On July...
07-08 04:29
